机构:[1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China[2]Department of Oncology, Henan Cancer Hospital, Zhengzhou 450003, China河南省肿瘤医院[3]Department of Gastroenterology and Urology, Hunan Cancer Hospital, Changsha 410013, China[4]Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China[5]Department of Oncology, Tianjin People’s Hospital, Tianjin 300122, China[6]Department of Oncology, Anhui Provincial Cancer Hospital, Hefei 230031, China[7]Department of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China[8]Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450099, China[9]Department of Oncology, Hubei Cancer Hospital, Wuhan 430079, China[10]Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China江苏省人民医院[11]Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110002, China[12]Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China浙江大学医学院附属第一医院[13]Department of Medical Oncology, Shandong Cancer Hospital, Jinan 250117, China[14]Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China苏州大学附属第二医院[15]Medical Oncology Department of Gastrointestinal Cancer, Liaoning Cancer Hospital, Shenyang 110801, China[16]Department of Medical Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453003, China[17]Department of Oncology, Peking University Shenzhen Hospital, Shenzhen 516473, China北京大学深圳医院深圳市康宁医院深圳医学信息中心[18]Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China[19]Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China[20]Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China[21]Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China浙江省肿瘤医院[22]Department of Gastrointestinal Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China河北医科大学第四医院[23]Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China[24]Department of Oncology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi 046000, China[25]Taizhou Hanzhong Biomedical Co., Ltd, Taizhou 225300, China[26]Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
This trial was sponsored by Taizhou Hanzhong Biomedical Co., Ltd. The
biomarker analyses were supported by the Major Project of Medical Oncology
Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences
(CICAMS-MOMP2022001).
第一作者机构:[1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Zhang Bo,Song Yan,Luo Suxia,et al.Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study[J].CELL REPORTS MEDICINE.2023,4(12):101301.doi:10.1016/j.xcrm.2023.101301.
APA:
Zhang Bo,Song Yan,Luo Suxia,Yin Xianli,Li Enxiao...&Huang Jing.(2023).Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study.CELL REPORTS MEDICINE,4,(12)
MLA:
Zhang Bo,et al."Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study".CELL REPORTS MEDICINE 4..12(2023):101301